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INTRODUCTION 
 
 The neuromuscular transmission has fascinated the 
anaesthesiologist ever since the usage of curare as a muscle 
relaxant in anaesthesia practise.  
CLAUDE BERNARD  in his series of the effects of curare on 
nerve muscle preparations suggested the  electrical 
transmission in the nerve and the presence of chemical 
molecule which is critical for the transfer of   information 
between nerve and  muscle. 
VULPAIN suggested the presence  of  a junction between 
terminal nerve and muscle and his suggestions were later 
confirmed from later studies.  
LANGLEY in 1905 explained and proved that a chemical 
molecule is present between nerve and the muscle to initiate a 
muscle contraction. 
 Succinylcholine is still one of the most commonly used 
muscle relaxant in clinical practice since its introduction by 
Theslaff and colleagues. Though being the fastest and short 
acting muscle relaxant it is not free of complications. 
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Fasciculation is an inevitable feature of Succinylcholine . It is 
because of this Succinylcholine induced muscle fasciculation 
that causes hyperkalemia, increased intra ocular pressure, 
increased intra cranial pressure, increased intra gastric 
pressure and myalgia. So by blunting this fasciculation we can 
avoid all the above mentioned complications of 
Succinylcholine. Several drugs has been used to blunt this 
Succinylcholine induced muscle fasciculation. They are 
Rocuronium, Atracurium, Ketorolac, Lignocaine, Diazepam, 
Magnesium  sulphate, Thiopentone, Diclofenac, small dose of 
Succinylcholine itself, Vecuronium, Pancuronium, and D-
Tubocurare. In our study we used Magnesium  sulphate at a 
dose of 40mg/kg to blunt this Succinylcholine induced muscle 
fasciculation. We used Propofol as an induction agent in our 
study because it has been shown in various studies that 
Propofol is a better agent than Thiopentone in reducing 
Succinylcholine induced muscle fasciculation.  
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AIM OF THE STUDY 
 
 The aim of our study is to study the role o f 
Magnesium  sulphate in attenuating   Succinylcholine 
induced muscle fasciculation and Succinylcholine 
induced post operative myalgia. In our study we have 
compared the effect of Magnesium  sulphate with 
Propofol and Propofol alone on Succinylcholine 
induced fasciculation and myalgia.  
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ANATOMY OF NEUROMUSCULAR 
JUNCTION 
 
  The neuromuscular junction is formed where a 
motor nerve travels as large myelinated axon  and 
meets the muscle fibre. 
 
 
 
 
Fig 3.1. NEUROMUSCULAR JUNCTION 
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ANATOMY OF NEUROMUSCULAR 
JUNCTION 
 
 The neuromuscular junction is specialized on the nerve 
side and on the muscle side to transmit and receive 
chemical messages.  
 Each motor nerve travels from the ventral horn of spinal 
cord to the neuromuscular junction as a large myelinated 
axon. 
 As it approaches the muscle it branches repeatedly to 
contact many muscle cells and gather them into a 
functional group known as MOTOR UNIT.  
 As the terminal reaches the muscle fiber, it loses its 
myelin sheath, forms a spray of terminal branches 
against the muscle surface and is covered by Schwann 
cells. 
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THE NEUROMUSCULAR JUNCTION  consists of three 
distinct parts: 
 
 PRE SYNAPTIC ZONE 
 SYNAPTIC CLEFT 
 POST SYNAPTIC ZONE 
 
These three components jointly form the neuromuscular 
junction, wherein   the signals from  nerve to muscle is 
transferred via the release of Acetylcholine and activate 
the Acetylcholine receptors.  
The nerve is separated from the muscle by a distance of 
20 nm and they are held together by a protein filament 
called BASAL LAMINA . The muscle membrane is 
deeply corrugated and as much as 5 million 
Acetylcholine receptors are densely packed  at the 
entrance of the cleft.  
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PRE SYNAPTIC ZONE: 
 
 The pre synaptic zone consists of the distal 
demyelinated segment of the motor nerve  and  is 
ensheathed  by  Schwann cell attaching the nerve 
end  to the muscle membrane.    
 Schwann cells  play an important role in 
regeneration of nerve terminal by releasing the 
nerve growth factor and neuregulin and cleans the 
pre synaptic zone by phagocytosis.  
 The motor nerve cytoplasm contains numerous 
synaptic vesicles filled with Acetylcholine and 
mitochondria. 
 
THE SYNAPTIC CLEFT: 
 
 The synaptic cleft occupies a space of   20 nm between 
the nerve and the muscle.  
 The cleft consists of   a basal lamina containing  
macromolecules that forms an  extracellular matrix 
which  aids cell adhesion and approximate 
neuromuscular signaling process. 
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 Acetylcholinesterase, alpha and beta isoforms , laminin, 
agrin  are necessary for appropriate neuromuscular 
transmission. 
 Acetylcholine is hydrolyzed by acetlycholinesterase in 
the synaptic cleft.  
 Acetlycholinesterase which is secreted from the muscles 
is attached to the lamina from where it rapidly breaks 
down the Acetylcholine. 
 In synaptic form of congenital myasthenia syndrome, 
cholinesterase is low. 
 Denervation decreases acetlycholinesterase  at the 
junctional and extrajunctional areas.  
 Organophosphate pesticides or nerve gas (eg- sarin ) 
inactivate acetlycholinesterase by phophorylating the 
serine hydroxyl group located at the active site of 
acetlycholinesterase. 
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POST SYNAPTIC ZONE: 
 
 The post synaptic membrane is characterized by 
numerous folds namely primary folds and  secondary 
folds 
 The shallower folds are called as primary and the 
deeper  folds are called as  secondary folds.  
 Both the folds increases the surface area for 
neuromuscular transmission.  
  Nicotinic Acetylcholine receptors are present in  
high concentration  in the shoulder region and are 
attached to the cell membrane by  cytoskeleton 
proteins. 
 PERIJUNCTIONAL ZONE  is present closer to the 
post synaptic membrane. 
 The perijunctional zone has a higher density of 
Sodium channels than the other parts of the cell 
membrane, making this part of the muscle membrane 
more capable of amplifying the responses to 
depolarization and thus to promote the transduction 
process that finally leads to muscle contraction.  
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HISTOLOGY OF NEUROMUSCULAR JUNCTION 
 
 
 
 
 
 The above shows the histological features of 
neuromuscular junction.  It shows the axon terminal in 
synaptic trough containing synaptic vesicles. These synaptic 
vesicles are filled with Acetylcholine molecules. It also shows 
the presence of numerous folds namely the primary and 
secondary folds. In deeper parts of the fold is the subneural 
cleft.  
Fig 3.2.  MICROSCOPIC VIEW OFNEUROMUSCULAR 
JUNCTION 
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STRUCTURE OF ACETYLCHOLINE 
RECEPTOR: 
 
 
 
 Each Ach receptor in the neuromuscular junction 
normally consists of five protein subunits namely 2 alpha 
and 1 beta, delta and epsilon. Only two identical alpha 
subunits are capable of binding to Ach molecules.  
Fig 3.3. STRUCTURE OF ACETYLCHOLINE 
RECEPTOR 
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 If both the alpha binding sites are occupied by Ach 
molecule, a conformational change in the subunits 
briefly (1ms) opens an ion channel in the core receptor.  
 The channel will not open if Ach is bound to only one 
alpha site. 
 In contrast to normal junctional receptor, another 
isoform contains a gamma subunit instead of epsilon 
subunit.  
 This isoform is termed as FETAL or IMMATURE  
receptor because initially it is expressed in fetal tissues.  
 It is also termed as EXTRAJUNCTIONAL RECEPTOR  
because it is located along the muscle membrane instead 
of neuromuscular junction. 
 
EXTRA JUNCTIONAL RECEPTORS: 
 
 Just before and shortly after birth and after denervation, 
the immature gamma containing Acetylcholine receptors 
are distributed all over the muscle membrane including 
the motor end plate and they are termed as EXTRA  
JUNCTIONAL RECEPTORS  
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 Nerve muscle contacts completely matures around 2 
years of age. 
 Denervation, burns, immobilization, chronic muscle 
relaxant therapy, stroke, sepsis leads to re -expression of 
these extra junctional receptors.  
 The muscle receptor has a life span of 2 weeks where as 
the newly developed extra junctional immature gamma  
Acetylcholine  receptors  have life span of 24 hours.  
 
PHYSIOLOGY OF NEUROMUSCULAR 
TRANSMISSION: 
 
 The region of approximation between a motor neuron and 
a muscle cell is the neuromuscular junction. The cell 
membranes of the neuron and muscle fibers are separated 
by a narrow (20 nm) gap namely synaptic cleft.  
 As the nerve’s action potential depolarizes its terminal, 
an influx of Calcium ions through voltage-gated Calcium 
channels into the nerve cytoplasm allows storage vesicles 
to fuse with the terminal membrane and release their 
contents of Acetylcholine (Ach). 
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 The Ach molecules diffuse across the synaptic cleft to 
bind with nicotinic cholinergic receptors on a specialized 
portion of the muscle membrane, the motor end plate.  
 Each neuromuscular junction contains approximately  5 
millions of these receptors.  
 
 
 
 
 
 The above image demonstrates the series of 
neuromuscular transmission. It shows the Sodium 
channel in closed state and open state. When the agonist 
Fig 3.4. SODIUM CHANNEL IN CLOSED & OPEN 
STATE 
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bind to the Sodium channel in closed state, the channels 
opens and influx of Sodium and Calcium ions and efflux 
of Potassium ions occur generating the action potential.  
 
 
 
 
 Cations flow through the open Ach receptor channel 
(Sodium and Calcium in; Potassium out), generating an 
END-PLATE POTENTIAL.  
 The contents of a single vesicle, a quantum of Ach (10 4 
molecules per quantum), produce a miniature end plate 
potential. 
Fig 3.5. CYCLE OF NEUROMUSCULAR 
TRANSMISSION 
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 The number of quanta released by each nerve impulse, 
normally at least 200 is very sensitive to extracellular 
ionized Calcium concentration; increasing Calcium 
concentration increases the number of quanta released.  
 When enough receptors are occupied by Ach, the end-
plate potential will be sufficiently strong to depolarize 
the perijunctional membrane.  
 Perijunctional areas of muscle membrane have a high 
concentration of Sodium channels. 
 The generated  action potential propagates along the 
muscle membrane and T-tubule system, which opens the 
Sodium channels and Calcium from sarcoplasmic 
reticulum 
 This intracellular Calcium facilitates the actin and 
myosin (contractile proteins) to interact producing 
muscle contraction. 
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METABOLISM OF ACETYLCHOLINE 
 
 ACETYLCHOLINESTERASE  rapidly degrades 
Acetylcholine into acetate and choline.  
 This enzyme is embedded into the motor end plate 
membrane immediately adjacent to Ach receptors.  
 Consequently, the receptor’s ion channels close, causing 
the end plate to repolarize.  
 As the generation of action potential ceases, the Sodium 
channels in the muscle membrane also closes.  
 Calcium gets sequestered in the sarcoplasmic reticulum.  
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PHARMACOLOGY OF SUCCINYLCHOLINE 
 
 Succinylcholine is a depolarizing neuromuscular 
blocker. It is the only clinically available depolarizing muscle 
relaxant. Structurally it is a two Ach molecules joined 
together through acetate methyl groups.  
 
 
 
 
 MECHANISM OF ACTION 
 
 Succinylcholine structurally resembles Acetylcholine  
molecule.  
 They bind to Ach receptors and generate a muscle action 
potential.  
Fig 4.1 STRUCTURE OF ACETYLCHOLINE 
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 Unlike Ach molecule, the Succinylcholine is not 
metabolized by acetlycholinesterase resulting in their 
increased concentration in synaptic cleft. This leads to 
prolonged depolarization of muscle end plate.  
 Continuous end plate depolarization causes muscle 
relaxation because the lower gate in the perijunctional 
Sodium channels is time limited.  
 After initial muscle excitation which is clinically seen 
as fasciculation, the Sodium channels close and cannot 
reopen until muscle is repolarized.  
 The end plate cannot repolarize until Succinylcholine is 
bound to Ach receptors. This results in muscle 
relaxation.  
 
DESENSITIZATION BLOCK 
 
 Desensitization block occurs when Acetylcholine 
receptors does not undergo any agonistic or 
conformational change upon stimulation by 
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Acetylcholine. The receptors become insensitive to 
agonistic effects of Acetylcholine. 
 The mechanism is still unkown. 
 Receptor randomly moves from resting to desensitized 
state constantly.  
 
PHASE II BLOCK 
 
 It is a complex phenomenon that occurs slowly at 
junction constantly exposed to depolarizing agents.  
 Upon repeated opening of channels by constant s timulant 
action of Acetylcholine, an abnormal electrolyte 
imbalance occurs that distorts the function of junctional 
membrane. 
 Factors affecting the development of PHASE II BLOCK 
include duration of exposure, the drug used and the type 
of muscle itself.  
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METABOLISM AND EXCRETION: 
 The main advantage with Succinylcholine is its rapid 
onset of action i.e. 30-60 sec and a shorter duration of 
action namely less than 10 minutes .  
 As the drug enters the circulation, it is rapidly 
metabolized by plasma cholinesterase into 
Succinylmonocholine.  
 This metabolism is so efficient that only a fraction of 
injected drug reaches the neuromuscular junction  to exert 
its effects.  
 Duration of action may be prolonged in high doses or by 
abnormal metabolism. The causes for abnormal 
metabolism are hypothermia, low plasma cholinesterase 
level or genetically different plasma cholinesterase.  
 Hypothermia decreases the rate of hydrolysis.  
 Low plasma cholinesterase is seen in pregnancy, liver 
disease, renal failure and interaction with certain drugs.  
 
DOSAGE: 
Intravenous route – 1-1.5 mg/kg body weight  
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PHARMACOLOGICAL EFFECTS OF 
SUCCINYLCHOLINE 
 
CARDIOVASCULAR EFFECTS 
 
 Because of its resemblance with Acetylcholine molecule, 
cardiovascular effects are due to stimulation of 
cholinergic receptors in the heart.  
 Cholinergic receptors are present in SA node of heart. By 
acting at this receptors, Succinylcholine can decrease the 
rate of sinus impulse generation, and reduce the rate of 
conduction leading to bradycardia.  
 This effect is more pronounced in patients with 
intrinsically high vagal tone such as paediatric patients 
and in adults this effect becomes prominent during 
second dose of Succinylcholine.  
 Therefore before repeating the second dose of 
Succinylcholine,  all adult patients must receive an 
anticholinergic drugs (e.g. atropine) to prevent  
bradycardia. 
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 Children are more prone for Succinylcholine induced 
bradycardia than adults.  Nodal rhythm or ventricular 
arrhythmias may develop. 
 
FASCICULATIONS: 
 
 The onset of paralysis by Succinylcholine is usually 
signaled by fasciculation which are nothing but visible 
motor unit contractions. 
 This muscle fasciculation is responsible for 
Hyperkalemia, muscle pain, increased intraocular 
pressure, increased intragastric pressure and increased 
intracranial pressure.  
 In our study we used Magnesium  sulphate to this 
attenuate fasciculation and its effects.  
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MUSCLE PAIN 
 Muscle pain (myalgia)   commonly presents 24 hours 
after surgery and it is more severe in ambulatory 
patients.  
 Higher incidence is seen in females, outpatients and 
large muscular patients. Incidence is less among 
paediatric, geriatric and pregnant women.  
 The pain is thought to be due to unsynchronized muscle 
contractions and occurs in unusual sites, such as the 
diaphragm, intercostal  muscles and interscapular region.  
 There may increase in serum creatine kinase levels 
following administration of Succinylcholine( indicative 
of muscle damage).   
 Several measures have been tried to reduce the 
fasciculation such as Rocuronium, Atracurium, 
Ketorolac, Lignocaine, Diazepam,Magnesium  Sulphate, 
Thiopentone, Diclofenac, small dose of Succicylcholine 
itself, Vecuronium, Pancuronium, and D-Tubocurare. 
 Rocuronium o.06-0.1 mg/kg prior to Scoline has been 
reported to be effective in preventing fasciculation and 
myalgia.  
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HYPERKALEMIA 
 
 Administration of Succinylcholine causes rise in serum 
K
+
 level of around 0.5 – 1.0 mEq/L.  
 The reason for rise in serum K+ is due to Succinylcholine 
induced muscle fasciculation.  
 This rise in serum K+ level can be life threatening in 
patients with pre- existing hyperkalemia, burns, massive 
trauma, neurological disorders.  
 This rise in serum K+ level can lead to cardiac 
arrhythmias and cardiac arrest.  
 This hyperkalemia induced cardiac arrest may be 
refractory to routine cardiopulmonary resuscitation.  
 
Conditions predisposing to Succinylcholine induced 
Hyperkalemia:  
 Burns 
 Massive trauma 
 Severe intraabdominal infections 
 Spinal cord injury 
 Encephalitis 
 Stroke 
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 Guilliane-Barre syndrome 
 Severe Parkinson’s disease  
 Tetanus 
 Prolonged immobilization 
 Ruptured cerebral aneurysm 
 Closed head injury 
 Myopathies 
 
MALIGNANT HYPERPYREXIA 
 It occurs in susceptible individuals with a congenital 
abnormality, particularly when it is used with volatile 
agents like Halothane. 
 Heat production exceeds heat loss and there is 
temperature rise of at least 2
o
 C/ hour. 
 It is an inherited autosomal dominant disorder related to 
the Calcium channels 
 It is characterized by following features :  
 Initially spasm of masseter muscle will occur  
 Rapidly rising temperature 
 Cyanosis 
 Mottled skin rashes 
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 Muscle rigidity in spite of relaxation  
 Hyperventilation 
 Hypercapnia 
 Dysrrhythmias 
 Acidosis 
 Death due to exhaustion and cardiac failure.  
 
INCREASED INTRA-OCULAR PRESSURE 
 The degree of increase in intra-ocular pressure following 
Succinylcholine 1.0 mg /kg is 4–8 mm Hg.  
 The cause of rise in intraocular pressure is due to 
extraocular muscle contraction. The increase occurs after 
intravenous injection, peaking at 1–2 min.  
 This increase in intraocular pressure may result in  
expulsion of intraocular contents in patients with 
penetrating eye injury.  
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INCREASED INTRAGASTRIC PRESSURE 
 Abdominal muscle fasciculation causes 
Succinylcholine-induced increase in intragastric 
pressure.  
 It never crosses 19 cm H2O. 
 The increase in intragastric pressure is not 
predictable.  
 However, there is no increased risk of aspiration 
because of corresponding increase in tone of the 
lower esophageal sphincter , resulting in an 
increase in barrier pressure.  
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PHARMACOLOGY OF MAGNESIUM  
SULPHATE 
Magnesium  is the second most common intracellular cation 
after Potassium. Magnesium  plays an important role  in many 
enzymatic reactions as a cofactor. It plays an important role in  
energy metabolism and nucleic acid synthesis. It is also 
involved in several processes including: hormone receptor 
binding, gating of Calcium channels, transmembrane ion flux, 
muscle contraction, neuronal activity, control  of vasomotor 
tone, cardiac excitability and neurotransmitter release.  
Magnesium  is distributed principal ly in bone (53%), 
intracellular compartments of muscle (27%) and soft tissues 
(19%). Serum Magnesium  comprises only 0.3% of total body 
Magnesium  stores. It is present in 3 forms  
1. Ionized (62%) 
2. Protein bound(33%),mainly albumin 
3. Bound to citrate and phosphate (5%) 
Magnesium  is absorbed in the ileum and colon. Its absorption 
is inversely proportional to intake. Excretion occurs via the 
kidney .Along with the other cations Magnesium  is filtered at 
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the glomerulus, but reabsorption occurs in the ascending loop 
of Henle and not the proximal convoluted tubule.  
 
CHEMICAL STRUCTURE OF MAGNESIUM  
SULPHATE: 
 
 
Magnesium  in its many of its properties mimics a 
physiological Calcium antagonist.  A common pathway for 
the release of hormones, growth factors, and neurot ransmitters 
is phospholipase C activation and hydrolysis to ionositol 4,5 
triphosphate (IP3). This (IP3) binds to the Calcium channels 
and releases Calcium. Magnesium  is a non-competitive 
inhibitor of the (IP3) gated Calcium channel. It may also 
Fig 5.1 STRUCTURE OF MAGNESIUM  SULPHATE 
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inhibit the Ryanodine receptors to release Calcium ions in the 
sarcoplasmic reticulum. 
Only 0.3% of the total body Magnesium  is available in serum 
for estimation. Hence estimation of serum levels does not 
reflect the total body Magnesium  stores. Normal serum 
Magnesium  levels are 1.5 – 2.5 mEq/L. When the levels are 
below 1.5mEq/L it is called as HYPOMAGNESEMIA . When 
the levels are greater than 2.5mEq/L it is termed as 
HYPERMAGNESEMIA . Another parameter for estimation is 
24hr urinary Magnesium  concentration which is 5-15 
mEq/24hr. 
 
MAGNESIUM DEFICIENCY: 
Magnesium  deficiency is often multifactorial and is usually 
found to coexist along with other electrolyte abnormalities, 
particularly hypokalemia or hypophoshatemia. Following are 
the causes for Magnesium  deficiency (i).reduced intake 
(ii).poor g.i.absorption (iii) increased loss  through diarrhoea, 
vomiting (iv) increased renal loss (v).diabetes mellitus (vi) 
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alcoholism (vii) drug induced – diuretics, amino glycosides 
etc, 
 
Clinical features: (i) usually associated with hypocalcemia and 
hypokalemia (ii) arrhythmia- Torsades de pointes, a 
polymorphic ventricular tachycardia (iii) neurologic 
manifestations include altered mentation, seizures, tremors 
and hyperreflexia.  
 
A serum concentration of less than 1 mEq/L is t reated with 6 g 
Magnesium  sulphate in 250 ml isotonic saline and infused 
over 3 hours followed by 5 g Magnesium  sulphate over next 
12 hours. Continue with 5 g Magnesium  sulphate every 12 
hours for next 5 days. Urine output and respiratory rate are 
monitored. 
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MAGNESIUM TOXICITY: 
 
Serum Magnesium  levels more than 2.5 mEq/L is termed as 
HYPERMAGNESEMIA . 
 Following are the causes:  
 hemolysis from hemolytic anemia or trauma 
 renal insufficiency 
 diabetic ketoacidosis 
 adrenal insufficiency 
 hyperparathyroidism 
 Lithium intoxication. 
 
Following are the clinical features:  
 
Manifestation Serum Magnesium  (mEq/L) 
Hyporeflexia >4 
1 st degree AV block >5 
Complete heart block >10 
Cardiac arrest  >13 
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MANAGEMENT   
 Hemodialysis is the treatment of choice for severe 
hypermagnesemia 
 Intravenous Calcium gluconate 1 g over 2-3 mins is used 
to antagonise the cardiovascular effects  
 Aggressive volume infusion with diuretic like 
furosemide. 
 
MAGNESIUM  SULPHATE IN OBSTETRICS: 
 
 Magnesium  sulphate remains the drug of choice in the 
treatment eclampsia. 4 to 6 gm i.v.  
 Magnesium  sulphate is diluted in 100 ml of normal 
saline given over 15 mins. This is followed by infusion 
of 2 gm/hr i.v. in 100 ml normal saline.  
 Target serum Magnesium  levels are 4 to 7 mEq/L.  
 Another alternative regimen is Pritchard s  regimen: 4gm 
Magnesium  sulphate given slow i.v. followed by 10 gm, 
of which 5 g is given in each buttock as deep 
i.m.injection.  
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 Use of Magnesium  sulphate in cases of pre-eclampsia is 
yet to be proven. 
 Magnesium  sulphate is known to have tocolytic effect. 
An i.v. Bolus of 2-4 g over 24 hrs followed by 1-2 g/hr i 
.v.infusion and is regulated based on uterine responses.  
 Observational studies have proven the decrease in 
incidence of cerebral palsy in low birth infants in 
mothers treated with Magnesium  sulphate. 
 
MAGNESIUM SULPHATE IN CARDIOLOGY: 
 It acts on Calcium channels in the myocardial muscle and 
also acts 
Indirectly on the cardiac muscle by inhibiting the 
Calcium uptake on the Troponin C of the myocytes and   
thereby influencing   myocardial contractility.  
 Its vasodilatory action is due to its activation of cyclic 
AMP. This causes reduction in systolic blood pressure.  
 Pulmonary vascular resistance is unaltered. Coronary 
vascular resistance is reduced and causes vasodilation. 
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Uses:  
  In acute Myocardial infarction – 2 gm Magnesium  
sulphate is administered intravenously over 5 to 15 mins 
followed by 18 gm over 24 hours.  
 In the treatment of arrhythmias-(i) Torsades de pointes 
intravenously 25 to 50 mg/kg, can be given up to 2 
gm.(ii) in atrial or ventricular arrhythmias along with 
hypokalemia. 
 Hypomagnesaemia is common after  CABG, hence it is 
used in postoperative period to prevent arrhythmias.  
 
MAGNESIUM IN NEUROMUSCULAR 
BLOCK: 
 
 Magnesium  ions have an inhibitory effect on 
postjunctional potentials and decrease in muscle fibre 
membrane excitability.  
 It also has a preponderant action on presynaptic 
potentials by competitively blocking the entry of 
Calcium ions. 
37 
 Presynaptic inhibition in release of Acetylcholine 
decreases the effect on postsynaptic receptors which in 
turn increases the threshold of axonal excitation, thereby 
potentiating the neuromuscular blockade action.  
 By acting as a Calcium antagonist it reduces the 
Succinylcholine induced muscle fasciculation. 
 
MAGNESIUM IN CENTRAL NERVOUS 
SYSTEM: 
 Magnesium  sulphate has been found to possess NMDA 
receptor antagonistic property thereby inhibits induction 
and central sensitization after nociceptive stimuli.  
 In many studies Magnesium  is found to possess the 
analgesic property when administered intravenous, 
intrathecal and epidural routes.  
 Intravenous dose of magnesium sulphate varies from 30 -
50mg/kg 
 In the neuraxial blockade a dosage of 50 mg has been 
found to have desired analgesia. Therefore this explains 
its use in intraoperative and postoperative analgesia.  
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 Magnesium  as already explained possesses anti-epileptic 
property in Eclampsia, although its effect on other types 
of seizures is yet to be proved.  
 
MAGNESIUM  IN RESPIRATORY SYSTEM: 
It has bronchodilatory action is due to  
 inhibition of smooth muscle Contraction  
 inhibition of histamine release from the mast cells  
 inhibition of Acetylcholine release from the cholinergic 
nerve endings.  
Hence  it is used in bronchial asthma. 
 
MAGNESIUM  DECREASES CATECHOLAMINE 
RELEASE: 
 Magnesium  is known to have marked anti adrenergic 
effect which is mediated by Calcium antagonism.  
 This anti-adrenergic property along with vasodilatory 
and anti-arrhythmic effect makes its use beneficial  in 
Pheochromocytoma. 
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 This property facilitates its use for nullifying the stress 
response for tracheal intubation. To reduce the stress 
response Magnesium  sulphate is given in a dose of 30-
50 mg/kg. 
 
PREPARATIONS AVAILABLE: 
 
Parenteral injection: Magnesium  sulphate- 10%, 12.5%, 50% 
For Intravenous use only- 4%, 8%.  
 Magnesium  sulphate in dextrose: 1% in 5%dextrose & 
2%in 5% dextrose. When administered intravenously the 
onset of action is immediate and duration of action is 30 
min. 
 On administration by intramuscular route the  onset of 
action takes 1hr and duration of action is 3-4 hrs. 
 Storage: 15-30o centigrade. For intravenous use 
concentration of 20% or less should be used. Rate of 
injection should be 1.5ml/hr.  
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DRUG INTERACTIONS: 
   Central nervous system depressants like Opiates, 
barbiturates are potentiated by Magnesium sulphate hence 
dose has to adjusted. 
   Neuromuscular blocker- they prolong the duration of 
neuromuscular blockade. 
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PHARMACOLOGY OF PROPOFOL 
 
Propofol is an intravenous non-barbiturate anaesthetic agent.    
Propofol (2,6-diisopropylphenol) consists of a phenol ring 
with two isopropyl groups attached. 
 
AVAILABLE FORMULATIONS : 
 
 Available as 1% or 2% solution in 10 ml, 20 ml vials. It 
is not water soluble.  
 It is supplied as white oil -in-water emulsion which is 
relatively thick and oily and so a 20G needle has to be 
used. 
 Originally polyethoxylated castor oil (Cremophor EL) 
was used for emulsification. Because of anaphylactic 
reaction caused by this, it has been replaced by 10% soya 
bean oil, 2.25% glycerol & 1.2% egg phosphatide 
(lecithin). 
 It is painful on injection that can be lessened by prior 
injection of xylocaine or mixing 2ml of 1% xylocaine 
18ml of Propofol. 
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 As Propofol preparations can support growth of bacteria 
it is advised to use only ampoules for dispensing and the 
contents must be used within 6 hours.  
 
PHARMACOKINETICS: 
 
 High lipid solubility results in onset of action that is 
almost equivalent to one – arm – brain circulation. Due 
to very short distribution half life awakening from single 
dose is rapid (2-8 mins). 
 The rate of clearance of Propofol exceeds hepatic blood 
flow because of the presence of extra hepatic 
metabolism.  
 High clearance rate explains rapid recovery after a 
continuous infusion.  
 It has a short initial distribution half life of 2 -8 minutes. 
 Metabolites of Propofol are excreted in urine. However 
excretion is not affected in chronic renal failure.  
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DOSAGE: 
    Induction dose -    2- 2.5 mg/kg 
    Maintenance dose – 150-300 microgram/kg/min 
    Sedation dose -   75-100 microgram/kg/min  
   
CLINICAL EFFECTS:  
CARDIOVASCULAR SYSTEM: 
 
 Propofol causes decrease in arterial blood pressure due 
to a drop in systemic vascular resistance , cardiac 
contractility and preload.  
 It increases the heart rate.  
 The relaxation of vascular smooth muscle is due to 
inhibition of sympathetic vasoconstrictor activity.  
 The negative ionotropic effect of Propofol may result 
from decrease in intracellular Calcium availability 
secondary to inhibition of trans sarcolemmal Calcium 
influx. 
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 Pressor responses to tracheal intubation  are reduced 
compared to Thiopentone. 
 It also reduces the hypertensive response to placement of 
LMA.  
 Patients with significant impaired ventricular function 
may experience a significant drop in cardiac output as a 
result of decreases in ventricular filling pressures and 
contractility.  
 Profound bradycardia and asystole after administration 
of Propofol have been described in healthy adult patients 
despite prophylactic anticholinergics. Treatment may 
require Isoproterenol.  
RESPIRATORY SYSTEM: 
 
 Propofol is a profound respiratory depressant that 
usually causes apnoea following an induction dose. 
Opioids may exaggerate this depression of ventilation.  
 Propofol infusion inhibits hypoxic ventilatory drive and 
depresses the normal response to hypercarbia.  
 Propofol inhibits the airway reflexes better than 
Thiopentone.  
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CEREBRAL EFFECTS: 
 
 Propofol decreases intracranial pressure by decreasing 
cerebral blood flow. 
 In patients with elevated intracranial pressure, Propofol 
can cause a critical reduction in CPP (cerebral perfusion 
pressure) to < 50 mm Hg unless steps are taken to 
support mean arterial pressure.  
 Propofol has a unique antipruritic property.  
 Since it has antiemetic property, it  is preferred in 
outpatient anaesthesia.  
 Induction is accompanied by excitatory phenomena like 
muscle twitching, spontaneous movements, opisthotonus 
or hiccupping possibly due to sub cortical glycine  
antagonism.   
 Propofol also has anticonvulsant property and has been 
successfully used to terminate status epilepticus.  
 It also has proconvulsant activity. The majority of 
Propofol induced seizures during induction of 
anaesthesia or emergence from anaesthesia reflect 
spontaneous excitatory movements of sub cortical origin. 
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HEPATIC AND RENAL FUNCTION: 
 
 Prolonged infusions of Propofol have been associated 
with hepatocellular injury accompanied by lactic 
acidosis, bradyarryhmias and rhabdomyolysis.  
 Prolonged infusion of Propofol may also result in 
excretion of green urine reflecting presence of phenols.  
 Urinary uric acid excretion may increase and may 
manifest as cloudy urine.  
 
DRUG INTERACTIONS: 
Fentanyl and Alfentanyl concentrations may be increased by 
concomitant administration of Propofol. Administration of 
Midazolam along with Propofol has synergistic effect. 
 
ADVERSE EFFECTS: 
 Allergic reactions occur due to phenyl nucleus and 
diisopropyl side chain. It is more common if there is 
prior sensitization to diisopropyl radical.  
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 PROPOFOL INFUSION SYNDROME –  
 
 It is characterized by lactic acidosis, 
rhabdomyolysis, and cardiac dysfunction. 
 It occurs most often in ICU where prolonged 
infusion of Propofol is given for sedation  
 It occurs when Propofol infusion is given at a dose 
> 75ug/kg/minute for more than 24 hours.  
 It can be suspected when there is unexplained 
tachycardia during infusion.  
 Arterial blood gas analysis and serum lactate levels  
confirms the diagnosis.  
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REVIEW OF LITERATURE 
 
1. Mahendra Kumar et  al
28  
  
60 patients were randomized into 2 groups. MG group 
received 40mg/kg of Magnesium  sulphate. NS group received 
same volume of normal saline. Muscle fasciculation occurred 
in 50% of patients in MG group and 100% of patients in NS 
group with a significant p-value of <0.001. After 24 hours 
surgery, no patient had myalgia in MG group and 30% of 
patients in NS group had myalgia with a significant p-value of 
<0.002. They concluded that Magnesium  sulphate 40mg/kg 
intravenously may be used with Propofol for induction of 
anaesthesia to control Succinylcholine induced fasciculation 
and myalgia. 
 
2. Danladi KY et al   
 
Eighty-four adult patients undergoing surgery under general 
endotracheal anaesthesia were randomly allocated into two 
study groups. Endotracheal intubation was performed with 
Succinylcholine in group A, while in group B Magnesium  
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sulphate followed by Succinylcholine. Samples are taken for 
estimating serum Potassium before induction and at 5 min 
after induction. Degree of muscle fasciculation and duration of 
apnea were assessed. This study showed increase in serum 
Potassium of Group A patients {average 0.34 mmol/L} from 
baseline with a p value 0.00 which was statistically 
significant. Magnesium  sulphate reduced Succinylcholine -
induced hyperkalemia  by 0.3 mmol/L (p-value 0.01). The 
severity of muscle fasciculation was also reduced significantly 
(p-value 0.00). The duration of apnea during endotracheal 
intubation (p-value 0.41) was not statistically significant. 
14.6% of patients who received Magnesium  complained of 
feeling of heat or warmth. The study showed that Magnesium  
sulphate administration has significantly reduced 
Succinylcholine-induced hyperkalemia and severity of muscle 
fasciculation during induction of general endotracheal 
anaesthesia. They advocated the use of Magnesium  
pretreatment in all patients at risk of these complications.  
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3. Stacey MR et al  
16  
 
Twenty patients were studied in a randomized double-blind 
manner to evaluate whether Magnesium  sulphate, attenuates 
the side effects caused by Succinylcholine when given during 
a rapid-sequence induction (RSI). Patients were allocated to 
two groups in a randomized manner.  One group received 
Magnesium  sulphate at a dose of 40mg/kg and the other group 
received equal volume of normal saline during rapid sequence 
induction. All the patients were induced with Thiopentone 
followed by Succinylcholine at a dose of 1.5mg/kg. The level 
of serum Potassium, the degree of fasciculation and the 
presence of postoperative myalgia(muscle pain) were 
recorded. The mean serum Potassium concentration increased 
by 0.08 mmol/L  in the Magnesium  sulphate group and by 0.1 
mmol/L in the normal saline group at 2 min afte r injection of 
Succinylcholine. The hemodynamic parameters like  blood 
pressure and heart rate increased in both groups after 
endotracheal intubation. The incidence of fasciculations was 
significantly lower in the Magnesium  sulpahte group. 
Duration of muscle relaxation was not prolonged however. 
There was no difference between the two groups in the 
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occurrence of myalgia after surgery (one patient in each 
group).  
 
4. Sakuraba S et al  
 
did a study to evaluate the effects of Magnesium  sulphate and 
precurarization with Vecuronium on Succinylcholine induced 
muscle fasciculations. 
Fifty-five patients were randomly allocated to three groups by 
a blinded manner. Group M received Magnesium  40 mg/kg in 
isotonic saline 100 ml for 5 min at 6.5 min before induction 
and subsequently administered isotonic saline 1 -2 ml at 1.5 
min before induction; Group V received isotonic saline 100 ml 
for 5 min at 6.5 min before induction and subsequently 
administered Vecuronium 0.02 mg/kg at 1.5 min before 
induction; Group C received isotonic saline 100 ml for 5 min 
at 6.5 min before induction and then saline 1 -2 ml at 1.5 min 
before induction. Fasciculation scores and mean changes of 
heart rate, systolic blood pressure and rate pressure product 
between baseline and after induction were significantly lower 
in group M than those in group C and group V. Pretreatment 
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with Magnesium  is more effective in reducing 
Succinylcholine-induced muscle fasciculation and subsequent 
tracheal intubation associated hemodynamic changes in rapid 
sequence induction compared with Vecuronium pretreatment.  
 
5. Tramer MR et al  
24  
 
42 patients undergoing elective abdominal hysterectomy under 
general anesthesia were randomly allocated into two groups. 
One group received 20% Magnesium  sulfate and other group 
received isotonic saline (control)  15 ml i.v before the 
commencement of surgery and infusion at a dose of 2.5 ml/h 
for the next 20 hours . Postoperative morphine requirement 
was assessed for 48 h using PCA(patient -controlled analgesia). 
Maximum expiratory flow (peak flow), pain at rest and  during 
peak flow, and discomfort were evaluated up to the 48th hour 
in the postoperative period , and 1 week and 1 month after 
surgery. Insomnia was evaluated after the first and second 
postoperative nights. Compared to control subjects, 
Magnesium -treated patients required less morphine during the 
first 48h (P<0.03), and experienced less discomfort during the 
first and second postoperative days (P<0.05-0.005). The 
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Magnesium -treated group showed no change in postoperative 
sleeping patterns when compared to preoperative patterns. 
Control patients showed an increase in insomnia during the 
first and second postoperative nights (P<0.002 and P<0.005, 
respectively) compared to preoperative values. They 
concluded that perioperative administration of Magnesium  
sulfate is associated with lesser analgesic requirement, less 
discomfort, and a better quality of sleep in the postoperative 
period with no adverse effects.  
 
6. James MF et al 
7  
 
did a study to evaluate role of Magnesium  sulphate in 
reducing Succinylcholine induced changes in serum Potassium 
concentration. The effect of Magnesium  sulfate 60mg/kg  on 
the neuromuscular blockade and subsequent Potassium release 
produced by 1.5 mg/kg Succinylcholine in ten normal patients 
was compared with ten patients pretreated with isotonic saline. 
Magnesium  had no significant effect on the duration of 
muscle relaxation. In control patients, serum Potassium raised 
by an average of 0.57 +/- 0.20 (SEM) mmol/L. No patient in 
the Magnesium  group had a raise in serum Potassium (mean 
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change -0.05 +/- 0.02 mmol/L). The difference between the 
two groups was statistically significant (p value <0.01).  
 
7. Tauzin-Fin P et al  
23  
 
30 ASA I or II patients undergoing radical prostatectomy 
under general anaesthesia were randomized into 2 groups 
namely Mg group and control C group. Mg group received 
Magnesium  sulphate at a dose of 50mg/kg diluted in 100 mL 
of isotonic saline over twenty minutes after induction of 
anaesthesia and before skin incision. Control group received 
equal volume of isotonic saline during the same period. At the 
end of surgery 40 ml of Ropivacaine wound infiltration was 
given in both the groups. Total requirement of tramadol in Mg 
group was 224 mg and C group was 446 mg 24 hours after 
surgery which was statistically significant( p -value of <0.001). 
They concluded that Magnesium  sulphate reduces tramadol 
consumption. 
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8. Maddineni VR et al
29
   
 
The incidence and severity of myalgia and change in creatine 
kinase levels were evaluated following administration of 1 
mg/kg of Succinylcholine  either immediately or 2 min after 
induction of anaesthesia with Propofol or Thiopentone in 
patients undergoing elective dental and ophthalmic surgery. In 
patients induced with Propofol ,the incidence of myalgia was 
35 and 60% when  Succinylcholine is given immediately and 
after 2 min respectively. In patients induced with Thiopentone 
the incidence of myalgia was 35 and 55% when 
Succinylcholine is given immediately and after 2 min. There 
was  no statistically significant differences among the groups. 
Creatine kinase levels increased in both the groups after the 
operative procedure with the least average increase in the 
group receiving Succinylcholine immediately after Propofol 
and the highest increase in the group receiving 
Succinylcholine 2 min after Thiopentone. There was no 
statistically significant correlation between the incidence and 
severity of muscle fasciculations, myalgia and changes in 
creatine kinase within or between the groups. They concluded 
that neither the induction agent nor the time between the 
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induction agent and Succinylcholine administration has any 
significant influence on the incidence of myalgia or creatine 
kinase elevation following Succinylcholine. 
 
9.  Y.-T. Jeon et al   
 
Sixty one children  with Cerebral palsy who underwent 
orthopedic surgery were randomly divided into 2 groups. The 
MgSO4 group (Group M) received Magnesium 
 sulphate 0.05g/kg   intravenously as a bolus and  0.015 
g/kg/h as a continuous infusion throughout the procedure . The 
saline group (Group S) received equal amount of isotonic 
saline. Rocuronium was administered at a dose of   600 ug/kg 
 as an  intubation dose  and 100 ug/kg as a  maintenance dose 
when TOF counts were more than 2 .  Intravenous   Fentanyl 
and Ketorolac were given for pain relief in the post operative 
period. Total analgesia consumption and pain scores were 
evaluated at postoperative thirty minutes, and at 6 hour, 24 
hour, and 48 hour.  The results obtained in the study was 
Rocuronium requirement in  MgSO4   group (Group M) was 
significantly less than saline group Group S [0.29 
(0.12) vs 0.42 (0.16) mg/kg/h, P<0.05].       Total  analgesic 
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consumption in MgSO4  group(Group M) was significantly less 
after surgery  at 24 hour and 48 hour  with a significant p- 
value of <0.05, and pain scores in  MgSO4   group (Group M) 
were lower than in saline group( Group S) during the 
postoperative period with a significant p-value of < 0.05. 
Serum Magnesium  (Mg) concentrations in MgSO4 group 
(Group M) were  higher until 24 hour after surgery  with a 
significant p- value of < 0.05. They concluded that 
intravenous Magnesium  sulphate reduces Rocuronium 
requirements and postoperative analgesic consumption in 
children with cerebral palsy.  
 
10. McClymont et al 
8  
 
48 adult female patients undergoing laparoscopic 
gynaecological surgery were randomly allocated into two 
groups. One group was induced with Thiopentone and other 
group was induced with Propofol. The results of their study 
showed that the incidence of Succinylcholine induced myalgia 
was low in Propofol group compared to Thiopentone group 
which was statistically significant with a p-value < 0.05.  
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MATERIALS AND METHODS  
 
 
 After approval of the study by our Institutional Ethics 
Committee, the study was conducted in 60 ASA grade I 
or II patients undergoing elective surgeries under general 
anaesthesia.  
 
 The age of the patients  ranged from 18– 60 years 
weighing 50 – 75 kg. 
 
 All patients were thoroughly evaluated preoperatively.  
 
 Informed written consent was obtained and the procedure 
was explained. 
 
 For all patients age, weight were noted.  
 
 In the preoperative assessment room, v ital parameters 
like pulse rate, blood pressure and baseline 
investigations like hemoglobin,  blood sugar, urea and 
creatinine, CXR and ECG were checked.  
 
 Thorough examination of all the systems and airway 
assessment was done. 
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 Exclusion criteria included patients not fulfilling 
inclusion criteria, patients with systemic disorders, and  
patients taking analgesics .  
 
Patients were randomly allocated into 2 groups namely  MG  
group and NS group 
 
MG GROUP:  
             
                Patients received Magnesium  sulphate 40mg/kg 
diluted to   10 ml with distilled water  
 
NS GROUP: 
 
                  
                Patients received 0.9% isotonic saline of volume 10 
ml. 
 
 
INCLUSION CRITERIA: 
 
 
• Age         :18 years to 60 years  
• ASA         : I & II  
• Surgery  : Elective 
• Who have given valid informed consent.  
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EXCLUSION CRITERIA: 
 
 
• Not satisfying inclusion criteria.  
• Patients with any systemic disease  
• Patients taking analgesics 
 
MATERIALS: 
 
• Magnesium  suphate 2ml ampoule (0.5g/ml)  
• Propofol vial 10ml (10mg/ml)  
• Succinylcholine  
• Neuromuscular monitoring device 
• Monitors – Pulse oximeter, NIBP, ECG 
• 2cc and 10cc syringes 
• 18 G intravenous cannula, 0.9% normal saline, 
Ringer lactate 
 
 In the operating room, appropriate equipment for airway 
management and emergency drugs were kept ready. Patients 
were shifted to the operating room .  Non-invasive blood 
pressure monitor, pulse oximeter and ECG leads were  
connected to the patient. Preoperative baseline systolic and 
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diastolic blood pressure, pulse rate and oxygen saturat ion were 
recorded. Patients were cannulated with 18 G intravenous 
cannula . All patients were preloaded with 500 ml of 
crystalloid solution.  
 
Patients in MS group received Magnesium  sulphate 40mg/kg 
diluted to 10 ml with distilled water over 10 minutes. Where as 
patients in NS group received 0.9% isotonic saline of volume 
10 ml over 10 minutes. Following which induction is done 
with Fentanyl 1.5 mcg/kg and Propofol 2mg/kg in both the 
groups. Then Succinylcholine was administered at a dose of 
2mg/kg. Patients were then observed for muscle fasciculations 
and graded as none, mild, moderate and severe .   
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PRIMARY OUTCOME MEASURES:  
 
                                                             
                 Fasciculations present or not 
 
1. Nil (absent) 
2. Mild (fine fasciculations of 
eyes, face , neck or fingers 
without movement of limbs)  
3. Moderate (obvious muscle 
twitching at more than one 
sites or movement of limbs)  
4. Severe (vigourous, sustained 
and widespread fasciculations)  
 
After 24 hours on the next day patients were assessed for 
postoperative  myalgia and graded as none , mild,  moderate 
and severe.  
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SECONDARY OUTCOME MEASURES:  
 
 
 Postoperative myalgia after 24 hours  
 Grading  
1. Nil (absence of pain) 
2. Mild (muscle stiffness or pain on specif ic 
questioning in nape of neck, shoulders and 
lower chest on deep breathing) 
3. Moderate (muscle stiffness and pain 
complained of by the patient spontaneously 
requesting analgesia) 
4.  Severe (incapacitating generalized muscle 
stiffness or pain)  
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OBSERVATION & ANALYSIS 
 
 
This prospective randomised double blinded study analyses the 
effectiveness of Magnesium  sulphate in attenuating 
Succinylcholine induced fasciculation and  post op myalgia.  
Results are expressed as mean and standard deviation. All t he 
statistical analysis was done using SPSS for Windows version 
15.0. The t- test was used for quantitative comparison.  Chi 
square test is used for qualitative comparison.          A   p - 
value of less than 0.05 is considered as significant 
statistically.  
60 Patients were taken into the study group, 30 belonged to 
the group MG and remaining 30 to group NS.  
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AGE DISTRIBUTION: 
 
 
 MG Group NS Group 
Mean 39.97 39.47 
Sd 10.78 12.43 
t-Value 0.17 
Df 58 
p-value 0.87 (Not Significant) 
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The mean age of group MG is 39.97 and the mean age of g roup 
NS is 39.47.     From the statistical data , it implies that p - 
value of Age distribution among NS and MG group is 0.60 
which is statistically not significant. Both the groups are 
comparable in terms of Age.  
 
 
Fig 9.1 GRAPHICAL REPRESENTATION OF AGE 
DISTRIBUTION 
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SEX DISTRIBUTION: 
 
Sex MG Group 
N=30 
NS Group 
N=30 
Total 
N=60 
N % N % N % 
Male 25 83.30 23 76.70 48 80.00 
Female 5 16.70 7 23.30 12 20.00 
Chi-square 
value 
0.42 
Df 1 
p value 0.52 (Not Significant) 
  
 
The percentage of male patients in MG group is 83.30% and in 
NS group is 80%. The percentage of female patients in MG 
group is 16.70% and in NS group is 20%,   p- value is 0.52 
which is statistically insignificant. Both the groups are 
comparable in terms of sex.  
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WEIGHT DISTRIBUTION: 
 
 
 
The mean weight of the patients in MG group is 62.30 and the 
mean weight of the patients in NS group is 66.65. The p - value 
is 1.00 which is statistically insignificant. Both the groups 
comparable in terms of weight.  
 
 
 MG Group NS Group 
Mean 62.30 66.65 
Sd 62.30 70.14 
t-Value 0.01 
Df 58 
p-value 1.00 (Not Significant) 
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ASA PS STATUS: 
 
 MG Group NS Group 
N % N % 
I 22 73.30 20 66.70 
II 8 26.70 10 33.30 
Total 30 100 30  
Chi square Value * 0.38 
Df 1 
Significant 0.57 (Not Significant) 
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22 patients in MG group and 20 patients in NS group belong to 
ASA I. 8 patients in MG group and 10 patients in NS group 
belong to ASA II. p- value is 0.57 which is statistically not 
significant. Both the groups are comparable in terms of ASA 
status. 
 
 
 
Fig 9.2. GRAPHICAL REPRESENTATION OF ASA PS 
STATUS 
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HEART RATE: 
 
* - Not Significant  
Heart Rate 
MG Group  
Mean ± sd 
NS Group  
Mean ± sd 
t-value 
p-Value 
df=58 
Base Line 
86.90  ±  
8.92 
89.57  ±  
11.70 
0.99 0.33* 
Before Induction 
79.97  ±  
8.68 
87.67  ±  
09.24 
3.33 0.002 
Post Induction 
90.73  ±  
7.88 
97.43  ±  
10.22 
2.84 0.01 
Post Intubation  1 
Mint 
100.33  ±  
8.47 
106.50  ±  
11.14 
2.41 0.02 
Post Intubation  3 
Mint 
90.73  ±  
7.43 
95.90  ±  
09.52 
2.34 0.02 
Post Intubation  5 
Mint 
85.30  ±  
6.64 
87.37  ±  
07.52 
1.13 0.26* 
72 
 
 
 
Heart rate is measured at  baseline, after giving MgSO4/before 
induction, post induction, post intubation at 1
s t
 , 3
rd
  and 5
th
 
minute. Calculated p- values are 0.33, 0.002, 0.01, 0.02, 0.02, 
0.26 respectively. Heart rate is statistically significant among 
the two groups during before induction, post induction, p ost 
intubation at 1
s t
 and 3
rd
 minute. 
 
 
 
Fig 9.3. GRAPHICAL REPRESENTATION OF HEART 
RATE 
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SYSTOLIC BLOOD PRESSURE: 
 
* - Not Significant  
Blood Pressure 
MG Group  
Mean ± sd 
NS Group  
Mean ± sd 
t-value 
p-Value 
df=58 
Base Line  
125.37  ±  
8.48 
126.83 ± 
08.90 
0.65 0.52* 
Before Induction 
121.00  ±  
6.87 
122.77 ± 
06.93 
0.99 0.33* 
Post Induction 
105.10  ±  
7.88 
103.57 ± 
06.37 
0.83 0.41* 
Post Intubation 1 
Mint 
113.50  ±  
9.41 
119.10 ± 
20.42 
1.36 0.18* 
Post Intubation 3 
Mint 
112.93  ±  
9.08 
113.60 ± 
09.43 
0.28 0.78* 
Post Intubation 5 
Mint 
107.73  ± 
5.91 
107.73  ± 
5.91 
0.01 1.00* 
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Systolic blood pressure is measured at  baseline, after giving 
MgSO4/before induction, post induction, post intubation at 1
s t
, 
3
rd
 and 5
th
 minute. Calculated p- values are 0.52, 0.33, 0.41, 
0.18, 0.78, 1.00 respectively. All the va lues are statistically 
not significant. 
 
 
 
Fig 9.4. GRAPHICAL REPRESENTATION OF 
SYSTOLIC BLOOD PRESSURE  
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FASCICULATION: 
 
 
 
 MG Group NS Group 
N % N % 
None 15 50.00 0 0 
Mild 8 26.70 7 23.30 
Moderate 7 23.30 20 66.70 
Severe  0 0 3 10.00 
Chi square Value * 24.33 
Df 3 
Significant 0.0001 (Significant)  
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15 patients had none, 8 had mild, 7 had moderate degree of 
fasciculation in MG group. 7 patients had mild, 20 had 
moderate, 3 had severe degree of fasciculation in NS group. p - 
value is 0.0001 which is statistically significant.  
 
 
 
 
Fig 9.5. GRAPHICAL REPRESENTATION OF 
FASCICULATION 
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POST OP MYALGIA AFTER 24 HRS 
 
 
 
 MG Group NS Group 
N % N % 
None 30 100.00 20 66.70 
Mild 0 - 07 23.30 
Moderate 0 - 03 10.00 
Chi square Value * 12.00 
Df 2 
Significant 0.002 (Significant) 
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No patients had post op myalgia in MG group. 7 patients had 
mild and 3 patients had moderate degree of post op myalgia in 
NS group. p- value is 0.002 which is statistically significant.  
 
 
 
 
 
 
Fig 9.6. GRAPHICAL REPRESENTATION OF POST 
OPERATIVE MYALGIA AFTER 24 HORS 
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DISCUSSION 
 
 Succinylcholine is one of the most commonly used 
muscle relaxant in clinical practice because of its faster onset, 
excellent muscle relaxation suitable for intubation and rapid 
recovery properties.  
 However use of Succinylcholine is not free of 
complications namely muscle fasciculation, post operative 
myalgia, hyperkalemia, increased intraocular pressure and 
increased intracranial pressure.  
 Pretreatment with several agents like Rocuronium, 
Atracurium, Ketorolac, Lignocaine, Diazepam,Magnesium  
Sulphate, Thiopentone, Diclofenac, small dose Of 
Succicylcholine itself, Vecuronium, Pancuronium, and D-
Tubocurare has been tried in order to reduce the 
Succinylcholine induced fasciculations and its complications. 
In our study we used Propofol as an induction agent because it 
has been found that Propofol is a better agent than 
Thiopentone in blunting the Succinylcholine induced 
fasciculations. 
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1. In our study, the mean age in MG group is 39.97and the 
mean age in NS group is 39.47 both are comparable in 
terms of age. 
 
2. The number of male patients in MG group is 25 and in 
NS group is 23. The number of female patients in MG 
group is 5 and in NS group is 7. Both are comparable in 
terms of sex. 
 
3. Mean weight of the patients in MG group is 62.30 and 
the mean weight of the patients in NS group is 66.65.  
 
4. Number of patients with ASA I in MG group is 22 and in 
NS group is 20. The number of patients with ASA II i n 
MG group is 8 and in NS group is 10. Both are 
comparable in terms of ASA PS status.  
 
5. There is significant reduction of heart rate in MG group 
during before induction, post induction, post intubation 
at 1
s t
 and 3
rd
 minute. 
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6. In our study 50% of patients in MG group had no 
fasciculations where as in NS group incidence of 
fasciculation was 100%.  
 
7. In our study 100% of patients in MG group had no post 
operative myalgia where as 33.30% patients in NS group 
had post operative myalgia.  
 
 Comparison of our results  with study conducted by 
Stacey et al
16  
 who used Magnesium  sulphate 40 mg/kg along 
with Thiopentone as induction agent shows that 40% of 
patients had no fasciculation in their study as against 50% in 
our study. After 24 hours no patients in MG group had 
myalgia and 9 patients in NS group had myalgia as against on 
difference in the incidence of myagia compared to our study. 
The reason for such difference in our study is Propofol is a 
better agent than Thiopentone in reducing the fasciculations.  
 
 Mantaki et al  
30  
used continuous Propofol infusion for 
treating Succinylcholine induced post operative myalgia.  
 Fasciculation produced by Succinylcholine can produce 
muscle damage resulting in increase in serum creatine kinase 
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levels and myoglobin level. Collier et al
21  
 observed that in 
patients who experience Succinylcholine induced post 
operative myalgia, there is transient fall in serum Ca
++
 levels 
at 1
s t
 minute. They postulated that influx of Calcium into the 
muscle cells causes the muscle damage and myalgia. At the 
neuromuscular junction Magnesium  has antagonistic action 
with Calcium. High Magnesium  at prejunctional site prevents 
the release of Acetylcholine from synaptic vesicles where as 
high Calcium promotes Acetylcholine release. Thus by acting 
as a Calcium antagonist Magnesium  sulpahte blunts the 
Succinylcholine induced muscle fasciculations.  
 
 Jay S. Dr De Vore. M.D. et al
14  
 (Anaesthesiolgy 52:76-
77, 1980) did a study on ten toxemic parturient who were 
treated with Magnesium  sulphate and who eventually 
underwent cesarean section under general anaesthesia. 
Magnesium  sulphate was given in a dose of 4g in the first 
hour i.v and then a maintenance dose at a rate of 1g/kg/hr 
infusion. Anaesthesia was induced with Thiopentone 
4mg/kg , followed by Succinylcholine 1.5mg/kg and 
patients were observed for fasciculations 1min following  
Succinylcholine. Results obtained were no patients had 
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muscle fasciculations. The mean serum Magnesium  level 
was 2.9-6.4mg/dl. 
 
 We didn’t measure serum Magnesium  levels in our 
study. There are studies which used a dose higher than our 
study and  showed no evidence of Magnesium  toxicity in 
their study. Tramer et al
24  
 studied Magnesium  levels after 
giving bolus dose of 3g followed by infusion at a rate of 
500mg/hour for 20 hours. The baseline Magnesium  level 
was 0.74 +/- 0.09  mmol/L. The Magnesium  levels after 20 
hour infusion was 1.34 +/- 0.09 mmol/L with no evidence of 
hypermagnesimia.  
 
 McClymont et al
8  
 conducted a study in 48 female 
patients undergoing laparoscopic gynaecological  surgeries  
to study the effect of Succinylcholine induced myalgia.  
Anaesthesia was induced with either Thiopentone or 
Propofol . the results were decrease  incidence of 
Succinylcholine induced fasciculation in patients induced 
with Propofol(19%) than patients induced with 
Thiopentone(63%) with a significant p-value <0.05. 
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SUMMARY 
 
From this prospective randomized double blinded study which 
evaluated the effect of  Magnesium  sulphate in attenuating 
Succinylcholine induced muscle fasciculation and post 
operative myalgia, we found that,  
 
1. The demographic profiles like Age, Sex, weight , ASA 
PS status are comparable in both the groups.  
 
2. There was 50% reduction in the incidence of muscle 
fasciculation in the group pretreated with Magnesium  
sulphate whereas the incidence of fasciculation was 
100% in the control group. 
 
3. The incidence of post operative Succinylcholine induced 
myalgia was 0% in group pretreated with Magnesium  
sulphate whereas there was 33.30% incidence of post 
operative myalgia in control group. 
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CONCLUSION 
 
 
From our study we conclude that MAGNESIUM SULPHATE  
at a dose of 40mg/kg effectively reduces the Succinylcholine 
induced muscle fasciculation and Succinylcholine induced 
post operative myalgia.  
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PROFORMA  
 
DATE:                                ROLL NO:                    Drug used: 
NAME:  
AGE:                           IPNO:                       SEX:                    
     
DIAGNOSIS: 
SURGICAL PROCEDURE DONE: 
 
PRE OP ASSESSMENT: 
HISTORY:    Any Co-morbid illness 
                     Any  
                      H/O previous surgeries 
 
MEASURES OF STUDY OUTCOME: 
 
                             HR         SPO2                    SBP          
   
BASELINE BEFORE MgSO4 
BEFORE INDUCTION 
POST IINDUCTION 
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POST INTUBATION 
             1 MIN: 
            3 MIN: 
            5 MIN: 
 
FASCICULATION: 
            NONE           MILD                 MODERATE                  SEVERE 
 
POST OP MYALGIA AFTER 24 HOURS 
            NONE            MILD               MODERATE                  SEVERE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
